Recombinant Mouse CD353/SLAMF8 Protein, N-His

Description of Recombinant Mouse CD353/SLAMF8 Protein, N-His

Introduction to Recombinant Mouse CD353/SLAMF8 Protein

Recombinant Mouse CD353/SLAMF8 Protein is a type I transmembrane protein that belongs to the signaling lymphocytic activation molecule (SLAM) family. It is encoded by the Slamf8 gene and is expressed on the surface of various immune cells, including T cells, B cells, natural killer (NK) cells, and dendritic cells. This protein plays a crucial role in regulating immune responses and has been studied extensively for its potential therapeutic applications.

Structure of Recombinant Mouse CD353/SLAMF8 Protein

The recombinant form of CD353/SLAMF8 protein is produced by cloning the Slamf8 gene into a suitable expression vector and expressing it in a host organism, such as E. coli or mammalian cells. The resulting protein is a glycosylated homodimer with a molecular weight of approximately 70 kDa. It consists of an extracellular domain, a transmembrane domain, and a cytoplasmic tail.

The extracellular domain of CD353/SLAMF8 protein contains two immunoglobulin-like domains, IgV and IgC2, which are responsible for its binding to ligands and other immune cells. The transmembrane domain anchors the protein to the cell membrane, while the cytoplasmic tail contains signaling motifs that are involved in downstream signaling events.

Activity of Recombinant Mouse CD353/SLAMF8 Protein

CD353/SLAMF8 protein is a multifunctional molecule that plays a critical role in immune cell signaling and activation. It is primarily known for its ability to bind to its ligand, CD229, on the surface of T cells, B cells, and NK cells. This interaction leads to the activation of various signaling pathways, including the PI3K/Akt and MAPK pathways, which regulate cell proliferation, survival, and cytokine production.

In addition to its role in immune cell activation, CD353/SLAMF8 protein has been shown to have inhibitory effects on T cell and NK cell function. It can bind to and inhibit the activity of the co-stimulatory molecule CD84, which is involved in T cell and NK cell activation. This dual function of CD353/SLAMF8 protein makes it a crucial regulator of immune responses.

Application of Recombinant Mouse CD353/SLAMF8 Protein

Due to its important role in immune cell signaling and activation, recombinant CD353/SLAMF8 protein has been studied for its potential therapeutic applications. One of the main areas of research is in the treatment of autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus. CD353/SLAMF8 protein has been shown to inhibit T cell and NK cell activity, which could help reduce the overactive immune response seen in these diseases.

Another potential application of recombinant CD353/SLAMF8 protein is in cancer immunotherapy. It has been reported that CD353/SLAMF8 protein is upregulated in certain types of cancer, including leukemia and lymphoma. By targeting and inhibiting its activity, it may be possible to suppress the growth and survival of cancer cells.

Furthermore, CD353/SLAMF8 protein has been shown to play a role in viral infections. It has been reported that CD353/SLAMF8 protein can interact with viral proteins and inhibit viral replication. This suggests that recombinant CD353/SLAMF8 protein could be used as a potential antiviral therapy.

Conclusion

Recombinant Mouse CD353/SLAMF8 Protein is a multifunctional protein that plays a critical role in regulating immune responses. Its structure, activity, and potential therapeutic applications make it a promising target for the treatment of various diseases, including autoimmune diseases, cancer, and viral infections. Further research and development of this protein may lead to the development of novel treatments and therapies for these conditions